Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus

Journal of Heart and Lung Transplantation

Volumn 24, Issue 10, 2005, Pages 1614-1618

  Mardigyan, Vartan ^a   Giannetti, Nadia ^a   Cecere, Renzo ^a   Besner, Jean Guy ^b   Cantarovich, Marcelo ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CEPT; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; GASTROINTESTINAL SYMPTOM; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL;

ADULT; AGED; AREA UNDER CURVE; CALCINEURIN; CARDIOMYOPATHIES; CYCLOSPORINE; DRUG INTERACTIONS; DRUG MONITORING; ENZYME INHIBITORS; HEART DISEASES; HEART NEOPLASMS; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; TIME FACTORS;

EID: 25844503898     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2004.12.112     Document Type: Article

References (29)

1. V.C. Cox, M.H. Ensom Mycophenolate mofetil for solid organ transplantation does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 25 2003 137 157
2. A. Keogh Calcineurin inhibitors in heart transplantation J Heart Lung Transplant 23 Suppl 5S 2004 S202 S206
3. B. Nashan, E. Cole, G. Levy, E. Thervet Clinical validation studies of Neoral C(2) monitoring a review Transplantation 73 9 Suppl 2002 S3 S11
4. M. Cantarovich, E. Elstein, B. de Varennes, J.S. Barkun Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients Transplantation 68 1999 1839 1842
5. D.O. Taylor, M.L. Barr, B.M. Meiser, S.M. Pham, R.M. Mentzer, A.L. Gass Suggested guidelines for the use of tacrolimus in cardiac transplant recipients J Heart Lung Transplant 20 2001 734 738
6. M. Cantarovich, J.G. Besner, J.S. Barkun, E. Elstein, R. Loertscher Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy Clin Transplant 12 1998 243 249
7. M. Cantarovich, J. Barkun, N. Giannetti, R. Cecere, J.G. Besner, J. Tchervenkov History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion Transplant Proc 36 2 Suppl 2004 442 447
8. M. Macchi-Andanson, B. Charpiat, R.W. Jelliffe, C. Ducerf, N. Fourcade, J. Baulieux Failure of traditional trough levels to predict tacrolimus concentrations Ther Drug Monit 23 2001 129 133
9. Y.M. Ku, D.I. Min An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants Ther Drug Monit 20 1998 219 223
10. R.E. Bullingham, A. Nicholls, M. Hale Pharmacokinetics of mycophenolate mofetil (RS61443) a short review Transplant Proc 28 1996 925 929
11. J.L. Beal, C.E. Jones, P.J. Taylor, S.E. Tett Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay Ther Drug Monit 20 1998 685 690
12. D. DeNofrio, E. Loh, A. Kao Mycophenolic acid concentrations are associated with cardiac allograft rejection J Heart Lung Transplant 19 2000 1071 1076
13. M.H. Yamani, R.C. Starling, M. Goormastic The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection Transplantation 69 2000 2326 2330
14. B.M. Meiser, M. Pfeiffer, D. Schmidt Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation importance of mycophenolic acid therapeutic drug monitoring J Heart Lung Transplant 18 1999 143 149
15. T. van Gelder, L.B. Hilbrands, Y. Vanrenterghem A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation Transplantation 68 1999 261 266
16. P. Halloran, T. Mathew, S. Tomlanovich, C. Groth, L. Hooftman, C. Barker Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups Transplantation 63 1997 39 47
17. P.J. Smak Gregoor, C.J. Hesse, T. van Gelder Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients Transplant Proc 30 4 1998 1192 1193
18. M. Rowland, T.N. Tozer Clinical pharmacokinetics concepts and applications 1989 Lea & Febiger Philadelphia 459 463
19. D.W. Cockroft, M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
20. P. Keown, D. Landsberg, P. Halloran A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group Transplantation 62 1996 1744 1752
21. K.M. Wong, C.C. Shek, K.F. Chau, C.S. Li Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients Am J Kidney Dis 35 2000 660 666
22. T. Pisitkun, S. Eiam-Ong, S. Chusil, K. Praditpornsilpa, P. Pansin, K. Tungsanga The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients Transplant Proc 34 2002 3173 3175
23. K. Jorgensen, J. Povlsen, S. Madsen C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients Nephrol Dial Transplant 17 2002 1487 1490
24. M.D. Aumente Rubio, J.M. Arizon del Prado, M.D. Lopez Malo de Molina Clinical pharmacokinetics of tacrolimus in heart transplantation new strategies of monitoring Transplant Proc 35 2003 1988 1991
25. G. Filler, N. Lepage, B. Delisle, I. Mai Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients Ther Drug Monit 23 2001 514 519
26. L.M. Shaw, D.W. Holt, M. Oellerich, B. Meiser, T. van Gelder Current issues in therapeutic drug monitoring of mycophenolic acid report of a roundtable discussion Ther Drug Monit 23 2001 305 315
27. T. Pawinski, M. Hale, M. Korecka, W.E. Fitzsimmons, L.M. Shaw Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus Clin Chem 48 2002 1497 1504
28. G. Filler, I. Mai Limited sampling strategy for mycophenolic acid area under the curve Ther Drug Monit 22 2000 169 173
29. G. Filler Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy Transpl Int 17 2004 120 125